Huang James, Rizk Nabil P, Travis William D, Riely Gregory J, Park Bernard J, Bains Manjit S, Dycoco Joseph, Flores Raja M, Downey Robert J, Rusch Valerie W
Department of Surgery, Thoracic Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
J Thorac Cardiovasc Surg. 2009 Jul;138(1):26-31. doi: 10.1016/j.jtcvs.2009.03.033.
Thymic carcinomas are considered to be more aggressive than thymomas and carry a worse prognosis. We reviewed our recent experience with the surgical management of thymic tumors and compared the outcomes and patterns of relapse between patients with thymic carcinoma and those with thymoma.
We performed a single-institution retrospective cohort study. Data included patient demographics, stage, treatment, pathologic findings, and postoperative outcomes.
During the period 1995-2006, 120 patients with thymic tumors underwent surgical intervention, including 23 patients with thymic carcinoma and 97 patients with thymoma, as classified according to the World Health Organization 2004 histologic classification. The overall 5-year survival was significantly different between patients with thymic carcinoma and those with thymoma (thymic carcinoma, 53%; thymoma, 89%; P = .01). Data on relapse were available for 112 patients. The progression-free 5-year survival was also significantly different between patients with thymic carcinoma and those with thymoma (thymic carcinoma, 36%; thymoma, 75%; P < .01). Using multivariate analysis, thymic carcinoma and incomplete resection were found to be independent predictors of progression-free survival. Relapses in patients with thymic carcinoma tended to occur earlier, and occurred significantly more frequently at distant sites than in patients with thymoma (60% vs 13%, P = .01).
Patterns of relapse differ significantly between patients with thymic carcinoma and those with thymoma, with lower progression-free survival, earlier onset, and more distant relapses in patients with thymic carcinoma. Given the greater propensity for distant failures, the inclusion of systemic therapy in the treatment of thymic carcinoma might take on greater importance. Despite significantly higher rates of distant relapse, good overall survival in patients with thymic carcinoma can be achieved.
胸腺癌被认为比胸腺瘤更具侵袭性,预后更差。我们回顾了我们近期对胸腺肿瘤手术治疗的经验,并比较了胸腺癌患者和胸腺瘤患者的预后及复发模式。
我们进行了一项单中心回顾性队列研究。数据包括患者人口统计学资料、分期、治疗、病理结果及术后预后。
在1995年至2006年期间,120例胸腺肿瘤患者接受了手术干预,其中23例为胸腺癌患者,97例为胸腺瘤患者,根据世界卫生组织2004年组织学分类进行分类。胸腺癌患者和胸腺瘤患者的总体5年生存率有显著差异(胸腺癌为53%;胸腺瘤为89%;P = 0.01)。112例患者有复发数据。胸腺癌患者和胸腺瘤患者的无进展5年生存率也有显著差异(胸腺癌为36%;胸腺瘤为75%;P < 0.01)。采用多因素分析,发现胸腺癌和不完全切除是无进展生存的独立预测因素。胸腺癌患者的复发往往发生得更早,且远处复发的频率明显高于胸腺瘤患者(60%对13%,P = 0.01)。
胸腺癌患者和胸腺瘤患者的复发模式有显著差异,胸腺癌患者的无进展生存率较低、复发出现更早且远处复发更多。鉴于远处转移失败的倾向更大,在胸腺癌治疗中加入全身治疗可能更为重要。尽管胸腺癌患者远处复发率明显更高,但仍可实现较好的总体生存率。